Evidence map›Paper›PMID 36844452›Full record

ArticleiScience2023

Anti-angiogenic collagen IV-derived peptide target engagement with α

Raquel Lima E Silva, Adam C Mirando, Stephany Y Tzeng, Jordan J Green, Aleksander S Popel, Niranjan B Pandey, Peter A Campochiaro

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Raquel Lima E SilvaDepartment of Ophthalmology and The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Adam C MirandoAsclepiX Therapeutics, Inc., Baltimore, MD, USA.
Stephany Y TzengDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jordan J GreenDepartment of Ophthalmology and The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Aleksander S PopelDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Niranjan B PandeyAsclepiX Therapeutics, Inc., Baltimore, MD, USA.
Peter A CampochiaroDepartment of Ophthalmology and The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of ActionR01EY028996 · NEI · JOHNS HOPKINS UNIVERSITY · PI Jordan Green · 2019 to 2026
$2.7M
Zeiss LSM780 Confocal Microscope for a Core FacilityS10OD016374 · OD · JOHNS HOPKINS UNIVERSITY · PI KUO, SCOT CHARLES · 2013 to 2013
$584k
NEI NIH HHS R01 EY028996NIH HHS S10 OD016374
6 · The paper itself

Abstract

AXT107, a collagen-derived peptide that binds integrins α

Indexed as

Biological sciencesCell biologyMolecular biologyNeuroscience

Identifiers

PMID36844452
PMCPMC9947312
OpenAlexW4318464329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.